Pharmalot

Pharmalot

Wealthy nations urged to embrace WTO deal and import meds made under compulsory licenses

By Ed Silverman

Pharmalot

Lilly lowers most insulin costs to $35 a month in response to Covid-19

By Ed Silverman

Pharma

Pharmalittle: India to allow limited exports of malaria drug; some Trump allies profit if hydroxychloroquine is approved

By Ed Silverman

Pharmalot

Former Novartis exec wants to repurpose generic drugs to fight Covid-19

By Ed Silverman

Pharmalot

WHO director-general endorses a voluntary intellectual property pool to develop Covid-19 products

By Ed Silverman

Pharmalot

Pharmalittle: States try to prevent hoarding of drug used for Covid-19; is BARDA ready for the coronavirus?

By Ed Silverman

Pharmalot

Gilead ramps up production of experimental Covid-19 treatment amid criticism over access

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Sanofi poised to supply millions of doses of malaria drug; Roche unit apologizes for ‘Wuhan’ virus label

By Ed Silverman

Pharmalot

Large employers could have saved money if more biosimilars had been prescribed

By Ed Silverman

Pharmalot

Pharmalittle: Novartis scraps generic sale to Aurobindo; another small study suggests old malaria drug works

By Ed Silverman

Pharmalot

The FDA warns Pfizer over yet another former Hospira manufacturing plant

By Ed Silverman

Pharmalot

FDA asks manufacturers to recall heartburn drugs over traces of a possible carcinogen

By Ed Silverman

Pharmalot

Pharmalittle: U.S. asks India to list restrictions on pharma ingredients; Giuliani wants FDA to fast-track a drug for Covid-19

By Ed Silverman

Pharmalot

A new Covid-19 problem: Shortages of medicines needed for placing patients on ventilators

By Ed Silverman

Pharmalot

Pharmalittle: A TB vaccine is tested against the coronavirus; FDA doesn’t punish Novartis over data integrity scandal

By Ed Silverman

Pharmalot

FDA closes review of Novartis data integrity scandal without punishing the drug maker

By Ed Silverman

Pharmalot

Pharmalittle: Drug pricing legislation is on the back burner; FDA issues emergency use for old malaria drugs

By Ed Silverman

Pharmalot

Roche backpedals and agrees to provide a solution for Covid-19 tests in the Netherlands

By Ed Silverman

Pharmalot

Pressure mounts to widen access to medical products that may combat Covid-19

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Conservative group pushes for malaria drug approval for Covid-19; OTC drug industry to get an overhaul

By Ed Silverman

Pharmalot

DEA proposes new rule to approve new suppliers of marijuana for research

By Ed Silverman

Pharmalot

Pharmalittle: Gilead asks FDA to rescind orphan status for Covid-19 drug; Bristol delays MS drug launch due to coronavirus

By Ed Silverman

Pharmalot

A Canadian bill would make it easier to issue compulsory licenses for Covid-19 products

By Ed Silverman

Pharmalittle: More clinical trials derailed by Covid-19; Pfizer jumpstarts tests on a drug to fight the pandemic

Opioid-overdose prescriptions may go unfilled due to the cost

Pharmalittle: WIPO holds talks to widen access to Covid-19 medical products; DEA moves to ease Covid-19 drug shortages

DEA moves to fight shortages of medicines needed for Covid-19 patients

Wealthy nations urged to embrace WTO deal and import meds made under compulsory licenses

Lilly lowers most insulin costs to $35 a month in response to Covid-19

Pharmalittle: India to allow limited exports of malaria drug; some Trump allies profit if hydroxychloroquine is approved

Former Novartis exec wants to repurpose generic drugs to fight Covid-19

WHO director-general endorses a voluntary intellectual property pool to develop Covid-19 products

Pharmalittle: States try to prevent hoarding of drug used for Covid-19; is BARDA ready for the coronavirus?

Gilead ramps up production of experimental Covid-19 treatment amid criticism over access

Up and down the ladder: The latest comings and goings

Pharmalittle: Sanofi poised to supply millions of doses of malaria drug; Roche unit apologizes for ‘Wuhan’ virus label

Large employers could have saved money if more biosimilars had been prescribed

Pharmalittle: Novartis scraps generic sale to Aurobindo; another small study suggests old malaria drug works

The FDA warns Pfizer over yet another former Hospira manufacturing plant

FDA asks manufacturers to recall heartburn drugs over traces of a possible carcinogen

Pharmalittle: U.S. asks India to list restrictions on pharma ingredients; Giuliani wants FDA to fast-track a drug for Covid-19

A new Covid-19 problem: Shortages of medicines needed for placing patients on ventilators

Pharmalittle: A TB vaccine is tested against the coronavirus; FDA doesn’t punish Novartis over data integrity scandal

FDA closes review of Novartis data integrity scandal without punishing the drug maker

Pharmalittle: Drug pricing legislation is on the back burner; FDA issues emergency use for old malaria drugs

Roche backpedals and agrees to provide a solution for Covid-19 tests in the Netherlands

Pressure mounts to widen access to medical products that may combat Covid-19

Up and down the ladder: The latest comings and goings

Pharmalittle: Conservative group pushes for malaria drug approval for Covid-19; OTC drug industry to get an overhaul

DEA proposes new rule to approve new suppliers of marijuana for research

Pharmalittle: Gilead asks FDA to rescind orphan status for Covid-19 drug; Bristol delays MS drug launch due to coronavirus

A Canadian bill would make it easier to issue compulsory licenses for Covid-19 products